-
1
-
-
17344363641
-
Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C
-
Piton A, Poynard T, ImbertBismut F, Khalil L, Delattre J, Pelissier E, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. HEPATOLOGY 1998;27:1213-1219.
-
(1998)
HEPATOLOGY
, vol.27
, pp. 1213-1219
-
-
Piton, A.1
Poynard, T.2
ImbertBismut, F.3
Khalil, L.4
Delattre, J.5
Pelissier, E.6
-
2
-
-
0033431808
-
Treatment of patients with chronic hepatitisCand normal ALT levels
-
Tassopoulos N. Treatment of patients with chronic hepatitisCand normal ALT levels. J Hepatol 1999;31(Suppl. 1):193-196.
-
(1999)
J Hepatol
, vol.31
, Issue.SUPPL. 1
, pp. 193-196
-
-
Tassopoulos, N.1
-
3
-
-
0029133788
-
-
The Hepatitis C Study Group. Ann Intern Med
-
Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995;123:330-337.
-
(1995)
Volunteer blood donors with antibody to hepatitis C virus: Clinical, biochemical, virologic, and histologic features
, vol.123
, pp. 330-337
-
-
Shakil, A.O.1
Conry-Cantilena, C.2
Alter, H.J.3
Hayashi, P.4
Kleiner, D.E.5
Tedeschi, V.6
-
4
-
-
0034761962
-
Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA
-
Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. HEPATOLOGY 2001;34:1000-1005.
-
(2001)
HEPATOLOGY
, vol.34
, pp. 1000-1005
-
-
Martinot-Peignoux, M.1
Boyer, N.2
Cazals-Hatem, D.3
Pham, B.N.4
Gervais, A.5
Le Breton, V.6
-
5
-
-
85005773666
-
Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels
-
Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000;118:760-764.
-
(2000)
Gastroenterology
, vol.118
, pp. 760-764
-
-
Persico, M.1
Persico, E.2
Suozzo, R.3
Conte, S.4
De Seta, M.5
Coppola, L.6
-
6
-
-
0034997693
-
Chronic hepatitis C with normal or abnormal aminotransferase levels: Is it the same entity?
-
Herve S, Savoye G, Riachi G, Hellot MF, Goria O, Lerebours E, et al. Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity? Eur J Gastroenterol Hepatol 2001;13:495-500.
-
(2001)
Eur J Gastroenterol Hepatol
, vol.13
, pp. 495-500
-
-
Herve, S.1
Savoye, G.2
Riachi, G.3
Hellot, M.F.4
Goria, O.5
Lerebours, E.6
-
7
-
-
0031952915
-
Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
-
Mathurin P, Moussalli J, Cadranel J-F, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. HEPATOLOGY 1998;27:868-872.
-
(1998)
HEPATOLOGY
, vol.27
, pp. 868-872
-
-
Mathurin, P.1
Moussalli, J.2
Cadranel, J.-F.3
Thibault, V.4
Charlotte, F.5
Dumouchel, P.6
-
8
-
-
72949124703
-
-
Consensus statement. Presented at EASL International Consensus Conference on Hepatitis C, Paris, February 26-27, 1999. J Hepatol 1999; 31(Suppl. 1):3-8.
-
Consensus statement. Presented at EASL International Consensus Conference on Hepatitis C, Paris, February 26-27, 1999. J Hepatol 1999; 31(Suppl. 1):3-8.
-
-
-
-
9
-
-
12444346656
-
Natural history of initially mild chronic hepatitis C
-
Alberti A, Benvegnu L, Boccato S, Ferrari A, Sebastiani G. Natural history of initially mild chronic hepatitis C. Dig Liver Dis 2004;36:646-654.
-
(2004)
Dig Liver Dis
, vol.36
, pp. 646-654
-
-
Alberti, A.1
Benvegnu, L.2
Boccato, S.3
Ferrari, A.4
Sebastiani, G.5
-
10
-
-
0034864360
-
The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: Spontaneous viral clearance and chronic HCV infection
-
Barrett S, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 2001;49:423-430.
-
(2001)
Gut
, vol.49
, pp. 423-430
-
-
Barrett, S.1
Goh, J.2
Coughlan, B.3
Ryan, E.4
Stewart, S.5
Cockram, A.6
-
11
-
-
0037383891
-
HCV carriers with persistently normal aminotransferase levels: Normal does not always mean healthy
-
Puoti C. HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy. J Hepatol 2003;38:529-532.
-
(2003)
J Hepatol
, vol.38
, pp. 529-532
-
-
Puoti, C.1
-
12
-
-
2142838857
-
Impaired quality of life in patients with chronic hepatitis C and persistently normal transminase levels [Abstract 606]
-
von Wagner M, Lee J-H, Fried R, Kronenberger B, Sarrazin C, Zeuzem S. Impaired quality of life in patients with chronic hepatitis C and persistently normal transminase levels [Abstract 606]. HEPATOLOGY 2003;38(4 Suppl. 1):454A.
-
(2003)
HEPATOLOGY
, vol.38
, Issue.4 SUPPL. 1
-
-
von Wagner, M.1
Lee, J.-H.2
Fried, R.3
Kronenberger, B.4
Sarrazin, C.5
Zeuzem, S.6
-
13
-
-
61749098966
-
Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels
-
Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. J Hepatol 2009;50:729-735.
-
(2009)
J Hepatol
, vol.50
, pp. 729-735
-
-
Kumada, T.1
Toyoda, H.2
Kiriyama, S.3
Sone, Y.4
Tanikawa, M.5
Hisanaga, Y.6
-
14
-
-
1542378867
-
PegIFN-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
-
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. PegIFN-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
-
(2004)
Ann Intern Med
, vol.140
, pp. 346-355
-
-
Hadziyannis, S.J.1
Sette Jr, H.2
Morgan, T.R.3
Balan, V.4
Diago, M.5
Marcellin, P.6
-
15
-
-
9644262441
-
PegIFN alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
-
Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. PegIFN alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724-1732.
-
(2004)
Gastroenterology
, vol.127
, pp. 1724-1732
-
-
Zeuzem, S.1
Diago, M.2
Gane, E.3
Reddy, K.R.4
Pockros, P.5
Prati, D.6
-
16
-
-
46149090112
-
Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France
-
Deuffic-Burban S, Deltenre P, Louvet A, Canva V, Dharancy S, Hollebecque A, et al. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol 2008;49:175-183.
-
(2008)
J Hepatol
, vol.49
, pp. 175-183
-
-
Deuffic-Burban, S.1
Deltenre, P.2
Louvet, A.3
Canva, V.4
Dharancy, S.5
Hollebecque, A.6
-
17
-
-
0032908398
-
Natural history of chronic hepatitis C
-
Pagliaro L, Peri V, Linea C, Camma C, Giunta M, Magrin S. Natural history of chronic hepatitis C. Ital J Gastroenterol Hepatol 1999;31:28-44.
-
(1999)
Ital J Gastroenterol Hepatol
, vol.31
, pp. 28-44
-
-
Pagliaro, L.1
Peri, V.2
Linea, C.3
Camma, C.4
Giunta, M.5
Magrin, S.6
-
18
-
-
0031960043
-
Determinants of outcome of compensated hepatitis C virus-related cirrhosis
-
Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. HEPATOLOGY 1998;27:1435-1440.
-
(1998)
HEPATOLOGY
, vol.27
, pp. 1435-1440
-
-
Serfaty, L.1
Aumaitre, H.2
Chazouilleres, O.3
Bonnand, A.M.4
Rosmorduc, O.5
Poupon, R.E.6
-
19
-
-
0033917644
-
Hepatitis C virus related cirrhosis: Time to occurrence of hepatocellular carcinoma and death
-
Degos F, Christidis C, Ganne-Carrié N, Farmachidi J-P, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000;47:131-136.
-
(2000)
Gut
, vol.47
, pp. 131-136
-
-
Degos, F.1
Christidis, C.2
Ganne-Carrié, N.3
Farmachidi, J.-P.4
Degott, C.5
Guettier, C.6
-
20
-
-
28844490547
-
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies
-
D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.
-
(2006)
J Hepatol
, vol.44
, pp. 217-231
-
-
D'Amico, G.1
Garcia-Tsao, G.2
Pagliaro, L.3
-
21
-
-
0035200712
-
Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States
-
El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. HEPATOLOGY 2001;33:62-65.
-
(2001)
HEPATOLOGY
, vol.33
, pp. 62-65
-
-
El-Serag, H.B.1
Mason, A.C.2
Key, C.3
-
22
-
-
72949085597
-
-
Accessed July 13, 2009
-
Global Health Observatory/WHOSIS. http://www.who.int/whosis/mort/ download/en/index.html. Accessed July 13, 2009.
-
Global Health Observatory/WHOSIS
-
-
-
23
-
-
79960830568
-
-
Accessed July 13, 2009
-
U.S. Centers for Disease Control and Prevention. Viral hepatitis. http://www.cdc.gov/ncidod/diseases/hepatitis/resource/PDFs/disease-burden.pdf. Accessed July 13, 2009.
-
Viral hepatitis
-
-
-
24
-
-
0030933395
-
-
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
-
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
-
-
-
-
25
-
-
0032748876
-
Hepatitis C virus genotypes in France: Relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP
-
Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, Coste J, Izopet J, Duverlie G, et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat 1999;6:435-443.
-
(1999)
J Viral Hepat
, vol.6
, pp. 435-443
-
-
Martinot-Peignoux, M.1
Roudot-Thoraval, F.2
Mendel, I.3
Coste, J.4
Izopet, J.5
Duverlie, G.6
-
26
-
-
0030912791
-
the Collaborative Study Group. Hepatitis C in a French population-based survey, 1994: Seroprevalence, frequency of viremia, genotype distribution, and risk factors
-
Dubois F, Desenclos JC, Mariotte N, Goudeau A, the Collaborative Study Group. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. HEPATOLOGY 1997;25:1490-1496.
-
(1997)
HEPATOLOGY
, vol.25
, pp. 1490-1496
-
-
Dubois, F.1
Desenclos, J.C.2
Mariotte, N.3
Goudeau, A.4
-
27
-
-
72949105424
-
Prevalence of hepatitis C in France, 2003-2004
-
Presented at the Vienna, Austria; April 26-30
-
Meffre C, Le Strat Y, Delarocque-Astagneau E, Meyer J, Coste D, Steinmetz J. Prevalence of hepatitis C in France, 2003-2004. Presented at the 41st annual meeting of the European Association for the Study of the Liver; Vienna, Austria; April 26-30, 2006.
-
(2006)
41st annual meeting of the European Association for the Study of the Liver
-
-
Meffre, C.1
Le Strat, Y.2
Delarocque-Astagneau, E.3
Meyer, J.4
Coste, D.5
Steinmetz, J.6
-
29
-
-
44949132603
-
Efficacy of peginterferon alpha-2a and ribavirin in 2101 patients with HCV infection in real-life clinical practice: Results of the French HEPATYS study [Abstract]
-
Bourliere M, Ouzan D, Rosenheim M, Doffoel M, Marcellin P, Pawlotsky JM, et al. Efficacy of peginterferon alpha-2a and ribavirin in 2101 patients with HCV infection in real-life clinical practice: results of the French HEPATYS study [Abstract]. HEPATOLOGY 2007;46:366A.
-
(2007)
HEPATOLOGY
, vol.46
-
-
Bourliere, M.1
Ouzan, D.2
Rosenheim, M.3
Doffoel, M.4
Marcellin, P.5
Pawlotsky, J.M.6
-
30
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FLJ, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
-
(2002)
N Engl J Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
Smith, C.4
Marinos, G.5
Goncales, F.L.J.6
-
31
-
-
0032547938
-
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
-
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
-
(1998)
N Engl J Med
, vol.339
, pp. 1485-1492
-
-
McHutchison, J.G.1
Gordon, S.C.2
Schiff, E.R.3
Shiffman, M.L.4
Lee, W.M.5
Rustgi, V.K.6
-
32
-
-
0032801727
-
Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials
-
Schalm SW, Weiland O, Hansen BE, Milella M, Lai FY, Hollander A, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 1999;117:408-413.
-
(1999)
Gastroenterology
, vol.117
, pp. 408-413
-
-
Schalm, S.W.1
Weiland, O.2
Hansen, B.E.3
Milella, M.4
Lai, F.Y.5
Hollander, A.6
-
33
-
-
11144358311
-
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
-
Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-1023.
-
(2004)
Gastroenterology
, vol.126
, pp. 1015-1023
-
-
Shiffman, M.L.1
Di Bisceglie, A.M.2
Lindsay, K.L.3
Morishima, C.4
Wright, E.C.5
Everson, G.T.6
-
34
-
-
38049012007
-
Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumption
-
Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008;48:200-207.
-
(2008)
J Hepatol
, vol.48
, pp. 200-207
-
-
Marcellin, P.1
Pequignot, F.2
Delarocque-Astagneau, E.3
Zarski, J.P.4
Ganne, N.5
Hillon, P.6
-
35
-
-
72949099103
-
-
March 8-12, Paris, France
-
Roudot-Thoraval F, Benoit J, Cattan L, Chazouillères O, Delfraissy JF, Filoche B, et al. Observatoire Adéquation: comparaison entre les recommandations de la conférence de consensus 2002 et la vie réelle du traitement anti-VHC Peginterferon alpha-2b (PegIFN). 32ièmes Journées Francophones de Pathologie Digestive; March 8-12, 2008; Paris, France.
-
(2008)
Observatoire Adéquation: Comparaison entre les recommandations de la conférence de consensus 2002 et la vie réelle du traitement anti-VHC Peginterferon alpha-2b (PegIFN). 32ièmes Journées Francophones de Pathologie Digestive
-
-
Roudot-Thoraval, F.1
Benoit, J.2
Cattan, L.3
Chazouillères, O.4
Delfraissy, J.F.5
Filoche, B.6
-
36
-
-
85056016967
-
Evolution des pratiques pour l'évaluation histologique des patients atteints d'hépatite chronique C traités entre 2003 et 2006: Analyse des 4546 patients des études Hepatys et Persee [in French] [Abstract]
-
Roudot-Thoraval F, Ouzan D, Denis J, Guyader D, Doffoel M, Delasalle P, et al. Evolution des pratiques pour l'évaluation histologique des patients atteints d'hépatite chronique C traités entre 2003 et 2006: analyse des 4546 patients des études Hepatys et Persee [in French] [Abstract]. Gastroenterol Clin Biol 2008;32:A92.
-
(2008)
Gastroenterol Clin Biol
, vol.32
-
-
Roudot-Thoraval, F.1
Ouzan, D.2
Denis, J.3
Guyader, D.4
Doffoel, M.5
Delasalle, P.6
-
37
-
-
33748883014
-
Review article: Management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity
-
Zeuzem S, Alberti A, Rosenberg W, Marcellin P, Diago M, Negro F, et al. Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity. Aliment Pharmacol Ther 2006;24:1133-1149.
-
(2006)
Aliment Pharmacol Ther
, vol.24
, pp. 1133-1149
-
-
Zeuzem, S.1
Alberti, A.2
Rosenberg, W.3
Marcellin, P.4
Diago, M.5
Negro, F.6
-
38
-
-
0037387851
-
Projecting future complications of chronic hepatitis C in the United States
-
Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-338.
-
(2003)
Liver Transpl
, vol.9
, pp. 331-338
-
-
Davis, G.L.1
Albright, J.E.2
Cook, S.F.3
Rosenberg, D.M.4
-
39
-
-
50549092907
-
Market uptake of new antiviral drugs for the treatment of hepatitis C
-
Lettmeier B, Muhlberger N, Schwarzer R, Sroczynski G, Wright D, Zeuzem S, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008;49:528-536.
-
(2008)
J Hepatol
, vol.49
, pp. 528-536
-
-
Lettmeier, B.1
Muhlberger, N.2
Schwarzer, R.3
Sroczynski, G.4
Wright, D.5
Zeuzem, S.6
|